Photo from Tom Powles/X
May 23, 2024, 13:33
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X:
“Neoadjuvant chemo/nivolumab with adjuvant nivolumab show high DFS (HR 0.58) and high pCR in NSCLC.
23% and 35% didn’t have surgery/adjuvant nivolumab respectively.
Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durvalumab/nivolumab/pembrolizumab) awaited.”
Source: Tom Powles/X
